日本脑髓母细胞瘤队列的分子和临床特征:使用经济/可访问的诊断方法进行子组特定的预后分层
Kohichi Go1, Asako Katsuma2, Ema Yoshioka2
1Department of Neurosurgery, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan.
Brain pathology (Zurich, Switzerland)
|March 11, 2026
概括
这项研究描述了日本脑髓母细胞瘤 (MB),这是一种儿科脑瘤,揭示了分子子组分布和预后标记. 一个新的分类器SEE-6-CNA有助于为个性化治疗提供成本效益高的风险分层.
科学领域:
- 儿科神经瘤学 儿科神经瘤学
- 癌症基因组学 癌症基因组学
- 分子诊断学 分子诊断
背景情况:
- 骨髓母细胞瘤 (MB) 是一种异质的儿科脑瘤,亚洲人群的综合分子数据有限.
- 以前的大规模研究主要集中在西方群体,需要区域分子子组分析.
研究的目的:
- 为了对一大批日本脑髓母细胞瘤病例进行分子子组分类.
- 在每个子组内识别特定的分子特征和预后标记.
- 为预后分层开发一种临床上可行的分类器.
主要方法:
- 使用NanoString基因表达,DNA甲基化阵列和基于MLPA的副本编号分析,对242MB病例进行集中分子分类.
- 使用有针对性的测序来补充分子表征.
- 基于MLPA的简化分类器 (SEE-6-CNA) 的开发和验证,针对6个位置.
主要成果:
- 小组分布:16.1%的WNT,24.8%的SHH,17.4%的第三组和41.7%的第四组.
- 确定了特定突变 (CTNNB1,MYCN,TP53) 和拷贝数变化 (单体6,染色体11损失) 与WNT,SHH,3组和4组MB的预后相关.
- 该SEE-6-CNA分类器展示了强大的预测分层能力.
结论:
- 日本的MB分子子组在很大程度上反映了全球发现,证实了保存的生物特征.
- SEE-6-CNA提供了一个具有成本效益的预后分层工具,并支持个性化治疗规划,特别是在资源有限的环境中.
- 分子分组对于理解MB异质性和指导治疗策略至关重要.
相关概念视频
Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Tumor Progression
3.4K
3.4K
Cancer Survival Analysis
808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808


